Development and Approval of Resmetirom for Treatment of Patients with MASH with Moderate to Advanced Liver Fibrosis
Time: 8:30 am
day: Conference Day Two
Details:
- Understanding the development of Resmetirom based on serial liver biopsy testing to provide unambiguous histopathological evidence and rigorously assess fibrosis regression and MASH resolution to accelerate FDA approval
- Diagnosing and monitoring patients using non-invasive tests to stratify patients and monitor treatment response, to differentiate between cirrhotic from non-cirrhotic MASH, empowering clinicians to identify high-risk patients earlier and tailor therapies, boosting real-world adoption
